Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut
Key facts
- Where
- Leuven, BelgiumSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07655375, who can take part
Where in Belgium
- University Hospitals LeuvenLeuven, BelgiumContact: Ine De Booser, MScTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Guy Boeckxstaens
- Trial code
- NCT07655375
- Record updated
- 10 September 2026
- Original description
Study evaluating the effect of UCB8600 on mast cell activation in the human gut:Read full original descriptionShow less
Study evaluating the effect of UCB8600 on mast cell activation in the human gut:
IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (spasmolytica), all of which have seen limited to no clinical success.
Recently, we were able to demonstrate that mast cells play an active role in IBS symptoms. More specifically, they set histamine free when activated which heightens nerve sensitivity in the intestines which probably contributes to the abdominal pain. A new product called "UCB8600" is hypothesized to be able to counteract this by causing less mast cells to be activated. In this study we'll test this by administering UCB8600 on intestinal tissue and see if there is less mast cell activation. If the study produces good results, this new product could potentially be used as a treatment for IBS in the future.
Inclusion: Voluntary written informed consent of the participant has been obtained prior to any screening procedures; At least 18 years of age at the time of signing the Informed Consent Form (ICF); Undergoing surgery for colorectal cancer; No preoperative radiotherapy or chemotherapy; Voluntary written informed consent of the subject has been obtained prior to any screening procedures; At least 18 years of age and maximum age of 65 years of age at the time of signing the Informed Consent Form (ICF); Diagnosed with IBS.
Exclusion: Using antihistamines such as ebastine, cetirizine, desloratadine, … (non-exhautive list) at the moment of surgery; Using antihistamines such as ebastine, cetirizine, desloratadine, … (non-exhausative list) at the moment of biopsy sampling. These should be stopped 2 weeks prior to the biopsy sampling; Inflammatory bowel disease (IBD) or diverticulitis; Diabetes or BMI ≥ 30 kg/m²; Subject is legally incapacitated; Subject has internal/external hemorrhoids at the moment of biopsy sampling; Using bloodthinners such as Acenocoumarol, Aspirine (acetylsalicylzuur), Apixaban (Eliquis), Clopidogrel (Plavix), Dabigatran (Pradaxa), Edoxaban (Lixiana), Rivaroxaban (Xarelto), warfarine (Marevan®) and Enoxaparine (Clexane), … (non-exhausative list); Subject is legally incapacitated.